← Research library

Integrative assessment of the effectiveness and safety of outpatient use of Picamilon

Randomized study in people · 2024

What was studied
44 stage I patients: 23 oral-only and 21 sequential parenteral/oral; 60 days of treatment
Main finding
Cognitive scores and sleep questionnaires improved during two active Picamilon schedules. There was no untreated or placebo group.

MoCA cognitive score · 24.9 → 26.5 → 28.3 points · Pooled active-treatment sample; the abstract does not map all three quoted values to specific visits · Reported serial assessments · p=0.022 and p<0.001 as reported

Reported findings and study design

Cognitive scores and sleep questionnaires improved during two active Picamilon schedules. There was no untreated or placebo group.

Open randomized comparison of 44 stage I cerebral-ischemia patients: oral-only 23; sequential intramuscular/oral 21; 60 days of treatment and a later follow-up.

Results · Publisher original abstract and selected HTML results checked; detailed table-by-table reconstruction remains open
MeasureResultComparison, timing and statistics
MoCA cognitive score24.9 → 26.5 → 28.3 pointsPooled active-treatment sample; the abstract does not map all three quoted values to specific visits · Reported serial assessments · p=0.022 and p<0.001 as reported
Sleep improvement50% at visit 3; 84% at visit 4Questionnaire-defined improvement; not measured sleep stages · End of 60-day treatment; then 1.5-month follow-up
Fedin neurological symptom score11.9 ± 8.3 → 6.0 ± 6.1 → 2.77 ± 4.43 pointsBaseline → visit 3 → visit 4 · p<0.0001 for both follow-up comparisons
Neurological improvement77% reported improvementWithin the treated sample
Autonomic-function normalization29%No significant difference between active schedules · p=0.024 as reported
Treatment completion44/44 completed23 oral-only and 21 sequential treatment
Tolerability and adverse events98% rated good tolerability; abstract reports <8.6% adverse eventsDenominator and event-versus-patient definition must be checked before converting to counts
Between-schedule sleep comparisonNo significant final differenceOral-only versus sequential treatment · p=0.508

These are changes during active treatment, not placebo-adjusted effects. The 2024 and 2025 patient series may overlap. Source percentage descriptions are retained without inventing adverse-event counts.

Source for these results ↗ · Reviewed 2026-11-01

Study limitations and source details

Study limitations

  • Open comparison of two active schedules; no placebo or untreated group.
  • Questionnaire sleep outcomes are not measured sleep stages.
  • Possible overlap with the 2025 report remains unresolved; do not sum cohorts.
  • Biomarker change does not demonstrate fewer cardiovascular events.

Related publications may describe some of the same participants or experiments.

Source details

Publisher HTML article

Publisher original abstract and selected HTML results checked; detailed table-by-table reconstruction remains open

Sources checked

Citation

Randomized trialFull text available

Danilov AB, Shindryaeva NN, Borodulina IV, Lunegov TD. Integrative assessment of the effectiveness and safety of outpatient use of Picamilon Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 124(7). PMID 39113452

Study source ↗ · DOI 10.17116/jnevro2024124071119 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards